Every 8-K that Journey Medical Corporation (DERM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DERM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DERM filings page.
Journey Medical Corporation reported second-quarter 2026 total revenue of $18.5 million, reflecting 23% growth from the prior-year quarter. Product revenue was $17.8 million and other revenue $0.7 million. Emrosi® contributed $8.1 million in revenue as prescription demand and payer coverage increased.
Income from operations was $0.5 million, compared with a $2.9 million operating loss a year earlier, while net loss narrowed to $0.3 million from $3.8 million. Non-GAAP Adjusted EBITDA turned positive at $2.9 million versus a loss of $0.5 million in the prior-year quarter. As of June 30, 2026, cash and cash equivalents were $25.6 million, total assets were $98.4 million, and stockholders’ equity was $32.1 million.
Journey Medical Corporation reported the results of its 2026 annual stockholder meeting held via virtual platform. Stockholders representing 16,145,526 shares of common stock and 6,000,000 shares of Class A common stock, together 81% of the 27,346,466 shares entitled to vote, were present, establishing a quorum.
All six director nominees were elected, each receiving over 31.7 million votes in favor, with broker non-votes of 6,515,971 for each nominee. Stockholders also ratified KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 39,374,407 votes for, 50,168 against, and 202,042 abstentions.
Journey Medical Corporation reported strong top-line growth for the first quarter ended March 31, 2026. Total revenue rose 21% year-over-year to $15.96 million, driven largely by Emrosi®, which contributed $6.3 million in revenue as its prescription demand and payer coverage expanded.
The company still posted a GAAP net loss of $2.23 million, but this improved from a $4.07 million loss a year earlier. Loss per basic and diluted share narrowed to $(0.08) from $(0.18). Operating loss declined to $1.49 million from $3.32 million, reflecting better operating leverage from higher sales and disciplined spending.
On a non-GAAP basis, Adjusted EBITDA turned positive at $0.62 million, compared with a $(0.94) million Adjusted EBITDA loss in the prior-year quarter. Cash and cash equivalents increased to $27.22 million from $24.09 million at December 31, 2025, supporting management’s view that the company is well-positioned to continue executing its dermatology-focused growth strategy.
Journey Medical Corporation reported a major expansion in payer coverage for Emrosi™, its oral treatment for inflammatory lesions of rosacea in adults. After securing a contract with a third major group purchasing organization, Emrosi™ payer access increased from approximately 100 million to over 150 million commercial lives as of April 1, 2026.
The company states that about 85% of all commercial lives in the United States now have access to Emrosi™, which it expects will support growth in total prescriptions, broader formulary adoption through 2026 and beyond, and reduced reliance on its co-pay bridging program.
Journey Medical Corporation reported full-year 2025 results with total revenues of $61.9 million, up from $56.1 million in 2024. Net loss narrowed to $11.4 million compared with $14.7 million a year earlier, and GAAP net loss per share improved to $0.47 from $0.72.
The company generated non-GAAP Adjusted EBITDA of $2.9 million, up from $0.8 million in 2024, reflecting higher product revenue and lower research and development spending. Cash and cash equivalents were $24.1 million as of December 31, 2025, compared with $20.3 million at year-end 2024.
Management highlighted the launch of Emrosi™, which generated $14.7 million in net revenues in 2025 after its early April launch, with approximately 53,000 prescriptions filled and payer access to over 100 million U.S. commercial lives.
Journey Medical Corporation furnished a press release providing a corporate update and its financial results for the three months ended September 30, 2025. The press release is included as Exhibit 99.1 to this report.
The information in this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” under the Exchange Act, and will not be incorporated by reference into Securities Act filings except as specifically referenced. The company’s common stock trades on the Nasdaq Capital Market under the symbol DERM.
Journey Medical Corporation entered into a Third Amendment to its Credit Agreement with SWK Funding LLC, updating the terms of its existing $25.0 million term loan, which has been fully drawn and is treated as a single Term Loan. The amendment extends the loan’s maturity date from December 27, 2027 to June 27, 2028, giving the company more time before final repayment is due.
Beginning in February 2026, the company must make quarterly principal payments equal to 7.5% of the funded Term Loan. However, if total revenue on a trailing twelve‑month basis exceeds $60.0 million as of December 31, 2025 (revised from $70.0 million), principal payments are deferred until February 2027, at which point quarterly payments increase to 10.0% of the funded amount (revised from 15.0%). These changes adjust how quickly the loan is repaid and link the timing and size of payments more closely to the company’s revenue performance.
Journey Medical Corporation entered a new at‑the‑market equity program, signing an At Market Issuance Sales Agreement with B. Riley Securities and Lake Street Capital Markets. Under this arrangement, the company may, at its discretion, offer and sell up to 3,750,000 shares of common stock through or to the agents under its effective Form S‑3 shelf registration and related prospectus supplement.
The agents are entitled to a 3.0% commission on gross proceeds from any share sales and are indemnified by the company, with certain expenses reimbursed. At the same time, Journey Medical terminated its prior at‑the‑market agreement with B. Riley that had allowed sales of up to 4,900,000 shares of common stock, under which 4,121,318 shares were sold from December 30, 2022 to August 28, 2025.
Journey Medical Corporation furnished a Current Report on Form 8-K stating that on August 12, 2025 the company issued a press release providing a corporate update and announcing its financial results for the three months ended June 30, 2025. The press release is furnished as Exhibit 99.1 to the report and the cover page interactive data file is furnished as Exhibit 104 (iXBRL). The report specifies the furnished information is not being "filed" under the Securities Exchange Act and is not subject to Section 18 liabilities.
The filing notes Journey Medical is an emerging growth company, lists its Nasdaq trading symbol as DERM and includes the registrant's business address and telephone number. The document is signed by Claude Maraoui, Chief Executive Officer, President and Director.
Journey Medical (NASDAQ:DERM) filed an 8-K detailing the June 24, 2025 annual meeting results and a Fourth Amended & Restated Certificate of Incorporation. Stockholders owning 85.0% of voting power approved three items:
- Election of six directors for one-year terms
- Ratification of KPMG LLP as 2025 auditor (32,468,451 for; 10,433 against)
- Adoption of the amended charter, which now exculpates corporate officers from certain personal liability
Total votes for the charter change were 25,373,988 for and 798,994 against, with 10,387 abstentions and 6,319,771 broker non-votes. The filing is effective upon Delaware acceptance and is furnished as Exhibit 3.1.
Journey Medical Corporation (NASDAQ: DERM) filed an 8-K reporting its forthcoming inclusion in the Russell 2000 and Russell 3000 indices, effective after the U.S. market close on June 27 2025. The change follows FTSE Russell’s annual reconstitution and does not involve any new financial results or transactions. Index inclusion typically increases stock visibility and can lead to incremental demand from passive funds benchmarked to the Russell family. The company attached the related press release as Exhibit 99.1; no other operational or financial updates were disclosed.